Accelerated antibiotic access for tens of thousands in battle against AMR

A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance (AMR).

The Global Antibiotic Research & Development Partnership (GARDP) and India-based Orchid Pharma have signed a sublicense agreement to manufacture cefiderocol, an antibiotic to treat certain Gram-negative infections.

This agreement is a critical step in an ambitious project by Japanese pharma major Shionogi (TYO: 4507) and the Clinton Health Access Initiative (CHAI) that aims to provide access to cefiderocol in a number of predominantly low- and middle-income countries, pending local authorization or national regulatory approval.